| Title |
Cannabinoids and Multiple Sclerosis
|
|---|---|
| Published in |
Molecular Neurobiology, June 2007
|
| DOI | 10.1007/s12035-007-0005-2 |
| Pubmed ID | |
| Authors |
Roger G. Pertwee |
| Abstract |
This review discusses clinical and preclinical evidence that supports the use of cannabinoid receptor agonists for the management of multiple sclerosis. In addition, it considers preclinical findings that suggest that as well as ameliorating signs and symptoms of multiple sclerosis, cannabinoid CB(1) and/or CB(2) receptor activation may suppress some of the pathological changes that give rise to these signs and symptoms. Evidence that the endocannabinoid system plays a protective role in multiple sclerosis is also discussed as are potential pharmacological strategies for enhancing such protection in the clinic. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 174 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Switzerland | 1 | <1% |
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 169 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 29 | 17% |
| Student > Master | 27 | 16% |
| Student > Bachelor | 21 | 12% |
| Student > Ph. D. Student | 18 | 10% |
| Other | 14 | 8% |
| Other | 34 | 20% |
| Unknown | 31 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 36 | 21% |
| Medicine and Dentistry | 32 | 18% |
| Biochemistry, Genetics and Molecular Biology | 13 | 7% |
| Neuroscience | 12 | 7% |
| Chemistry | 11 | 6% |
| Other | 33 | 19% |
| Unknown | 37 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2013.
All research outputs
#15,284,663
of 22,729,647 outputs
Outputs from Molecular Neurobiology
#2,043
of 3,435 outputs
Outputs of similar age
#58,945
of 68,355 outputs
Outputs of similar age from Molecular Neurobiology
#12
of 13 outputs
Altmetric has tracked 22,729,647 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,435 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 68,355 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.